Filter by
 

Type of content

Publication date

Keywords

Keywords

Target audience

NPS

Displaying 1 - 20 of 255

Publications

EMCDDA initial report on the new psychoactive substance 3-CMC

22.12.2021

1-(3-Chlorophenyl)-2-(methylamino)propan-1-one (3-chloromethcathinone, 3-CMC) is a synthetic cathinone stimulant. It is a ring-substituted cathinone, which is structurally related to methcathinone and 4-chloromethcathinone (4-CMC).

Publications

EMCDDA initial report on the new psychoactive substance 3-MMC

22.12.2021

2-(Methylamino)-1-(3-methylphenyl)propan-1-on (3-methylmethcathinone, 3-MMC) is a synthetic cathinone stimulant. It is a ring-substituted cathinone, which is structurally related to methcathinone and 4-methylmethcathinone (mephedrone).

Events

Meeting on the risk assessment of the new psychoactive substances 3-MMC and 3_CMC

18.11.2021

The extended Scientific Committee of the EMCDDA meets on 18-19 November 2021 to examine the risk assessment by the EMCDDA of the new psychoactive substances 3-MMC and 3_CMC.

Events

VIII International Conference on Novel Psychoactive Substances (NPS)

17.11.2021

The VIII International Conference on Novel Psychoactive Substances (NPS) takes place as a virtual event on 17-19 November 2021. The EMCDDA is represented at the conference's scientific committee.

Publications

Spotlight on… Fentanils and other new opioids

20.10.2021

New opioids are synthetic narcotic analgesics that have recently appeared on the drugs market, many of which are highly potent substances that pose a life-threatening risk of poisoning. Fentanils are a particularly potent group of synthetic opioids, which in some cases are used in human and...

Publications

Spotlight on… Synthetic cannabinoids

18.10.2021

Synthetic cannabinoids (or synthetic cannabinoid receptor agonists) is the name given to a diverse range of substances that act on the same brain receptors as tetrahydrocannabinol (THC), the main psychoactive ingredient in cannabis. This spotlight outlines key issues related to synthetic...

Events

Simpósio Brasileiro de Análises Toxicológicas - SIBRAT

04.10.2021

The Simpósio Brasileiro de Análises Toxicológicas (SIBRAT) (Brasilian Symposium of Toxicological Analysis)  takes place online on 4-6 October. The EMCDDA is represented a the symposium.  It is...

News

New report highlights public health and social risks posed by synthetic cannabinoids in Europe

09.09.2021

Synthetic cannabinoids come under the spotlight today in a new report released by the EU drugs agency (EMCDDA). Widely available across Europe and highly potent, these substances are placing some users at a ‘high risk of poisoning’, the agency warns. Synthetic cannabinoids are the largest group of...

Publications

Synthetic cannabinoids in Europe – a review

09.09.2021

This report provides a technical review of the current body of knowledge regarding synthetic cannabinoids that are monitored by the the EU Early Warning System. The aim of this report is to strengthen situational awareness of synthetic cannabinoids in Europe and to help stakeholders prepare for,...

Document library

Commission Delegated Directive (EU) 2021/802 on MDMB-4en-PINACA and 4F-MDMB-BICA

09.06.2021

This document links to the Commission Delegated Directive (EU) 2021/802 on MDMB-4en-PINACA and 4F-MDMB-BICA.

Media library

Timeline of benzodiazepines formally notified to the EU Early Warning System for the first time, 2007–2020

09.06.2021

This timeline, showing when different benzodiazepines were formally notified to the EU Early Warning System for the first time, is taken from the publication New benzodiazepines in Europe – a review. The source data for the timeline may be found below. Yearr of notification Name 2007...

News

New report highlights public health risks and increasing availability of ‘designer benzodiazepines’ in Europe

09.06.2021

New benzodiazepines, which are not controlled by international drug laws, come under the spotlight today in a new report released by the EU drugs agency (EMCDDA) (1). Often marketed as ‘designer benzodiazepines’, these substances are sold as ‘legal’ replacements for controlled benzodiazepines and...

Publications

New benzodiazepines in Europe – a review

09.06.2021

This report provides a technical review of the current body of knowledge regarding new benzodiazepines that are monitored by the EU Early Warning System. The aims of this report are to strengthen situational awareness of new benzodiazepines in Europe, and to help stakeholders prepare for and...

Events

Second training Neptune: Guidance on the Management of Acute and Chronic Harms of Club Drugs and New Psychoactive Substances

05.05.2021

The EU4Monitoring Drugs (EU4MD) project of the EMCDDA is co-organising the Second training Neptune: Guidance on the Management of Acute and Chronic Harms of Club Drugs and New Psychoactive Substances...

Document library

DARK classics in chemical neuroscience: etonitazene and related benzimidazoles

24.03.2021

News

European Commission proposes to control two harmful new psychoactive substances

12.03.2021

Today, the European Commission has proposed to control two harmful new psychoactive substances (NPS) across the European Union. The substances in question — MDMB-4en-PINACA and 4F-MDMB-BICA — are both synthetic cannabinoids, which have been raising health concerns in Europe (1). The proposal to...

Publications

Risk assessment report on a new psychoactive substance: methyl 2-{[1-(4-fluorobutyl)-1H-indole-3-carbonyl]amino}-3,3-dime- thylbutanoate (4F-MDMB-BICA) in accordance with Article 5c of Regulation (EC) No 1920/2006 (as amended)

12.03.2021

This risk assessment report presents the summary findings and the conclusion of the risk assessment carried out by the Scientific Committee of the EMCDDA on 4F-MDMB-BICA. The report is intended for policymakers and decision-makers in the institutions of the EU. Explanatory note: In the interests...

Publications

Risk Assessment Report on a new psychoactive substance: methyl 3,3-dimethyl-2-{[1-(pent-4-en-1-yl)-1H-indazole-3-car- bonyl]amino}butanoate (MDMB-4en-PINACA) in accordance with Article 5c of Regulation (EC) No 1920/2006 (as amended)

12.03.2021

This risk assessment report presents the summary findings and the conclusion of the risk assessment carried out by the Scientific Committee of the EMCDDA on MDMB-4en- PINACA. The report is intended for policymakers and decision-makers in the institutions of the EU. Explanatory note: In the...

Publications

EMCDDA operating guidelines for the risk assessment of new psychoactive substances

22.12.2020

The purpose of these guidelines is to ensure compliance with the scope and requirements of Regulation (EC) No 1920/2006 (as amended) and Council Framework Decision 2004/757/JHA (as amended) in respect to the risk assessment procedure for and reporting on new psychoactive substances. To...

Publications

EMCDDA technical report on the new psychoactive substance methyl 2-{[1-(4-fluorobutyl)-1H-indole-3-carbonyl]amino}-3,3-dimethylbutanoate (4F-MDMB-BICA)

21.12.2020

The purpose of this technical report is to provide an analysis of the available information on methyl 2-{[1-(4-fluorobutyl)-1H-indole-3-carbonyl]amino}-3,3-dimethylbutanoate (commonly known as 4F-MDMB-BICA), a synthetic receptor cannabinoid agonist that has recently emerged on the drug market in...

Loading